Drug Interaction:
Antiadrenergic agents ( Peripherally acting )include-
Reserpine, Guanithidine monosulphate, Guandrel sulfate, ( Alpha-1- blockers), Prazosin,Terazosin, Doxazosin, Tamsulosin, Silodosin, Alfuzosin Hcl
Refer - Prazosin
Concurrent use of potent CYP3A4 inhibitors( ie. ketoconazole, itraconazole, and ritonovir) can result in prolonged alfuzosin exposure and is therefore contraindicated
With the coadmin of atenolol, the Cmax and AUC of alfozosin increased by 28% and 21% respy
With dilitiazem the Cmax and AUC of alfuzosin are elevated 1.5 fold and 1.3 fold respy
Precautions should be taken when administred along with drugs that cause changes in QT interval
Both tadalafil and vardenafil are contraindicated for use with alfuzosin
Indication:
Benign prostatic hyperplasia
Antiadrenergic agents ( Peripherally acting )include-
Reserpine, Guanithidine monosulphate, Guandrel sulfate, ( Alpha-1- blockers), Prazosin,Terazosin, Doxazosin, Tamsulosin, Silodosin, Alfuzosin Hcl
Refer - Prazosin
LIST OF DRUGS DURING 2004
Sr.No- 200
Name of the Drug- Alfuzosin E.R Tablets (10mg)
Pharmacological Classification- For BPH
Date of Approval- 14-05-2004
Approved by U.S.FDA on 30-12-2004 (Ref- FDA approved List- 2004)
LIST OF DRUGS DURING 2007
Sr.No- 87
Name of the Drug- Alfuzocin HCL ER (10mg) +
Dutaseride o.5mg tablet
Pharmacological Classification- For BPH in men with enlarged prostrate
Date of Approval- 14-06-07
Approved by U.S.FDA on 30-12-2007 (Ref- FDA approved List- 2007)
Approved by (DCI) Drug Controller GENERAL - India For Marketing ( Ref- IDMA Publication)
Name of Drug Indication Date of Approval
1.Alfuzosin Hcl ER 10mg+ Dutasteride 0.5mg tablet 14-06-2007
For BPH in men with enlarged prostrate
2.Alfuzosin E.R. Tablets 10mg For BPH 14-05-2004
Adverse Reaction:
Alfozosin was well tolerated in clinical trials.
The most commonly reported vasodilator side effects include
orthoststic hypotension, headache, dizziness, and tachycardia
Contra-Indications:
Renal function impairment-
Systemic exposre was increased by approximately 50% in pharmacokinetic studies of patients with mild, moderate, severe heptic insufficiency.
Caution should be excercised when Alfuzosin is administered to patients with severe renal insufficiency
Hepatic function impairment-
Alfuzosin should not be given to patients with moderate to severe hepatic insufficiency.
The pharmcokinetics of alfuzosin have not been studied in patients with mild hepatic insufficiency
Dosages/ Overdosage Etc:
Indication
Benign prostatic hyperplasia
Dosage
Adults- recommended dose is 10mg daily to be taken immediately after the same meal each day
Elderly - no overall differences in safety or effectiveness were observed between elderly and younger subjects
Patient Information:
Antiadrenergic agents ( Peripherally acting )include-
Reserpine, Guanithidine monosulphate, Guandrel sulfate, ( Alpha-1- blockers), Prazosin,Terazosin, Doxazosin, Tamsulosin, Silodosin, Alfuzosin Hcl
Refer - Prazosin
Extended release - take immediately after the same meal each day. Swallow whole. Do not chew or crush
Pharmacology/ Pharmacokinetics:
Antiadrenergic agents ( Peripherally acting )include-
Reserpine, Guanithidine monosulphate, Guandrel sulfate, ( Alpha-1- blockers), Prazosin,Terazosin, Doxazosin, Tamsulosin, Silodosin, Alfuzosin Hcl
Refer - Prazosin
Pharmcology
Alfuzosin Hcl is quinazoline derivative. Alfuzosin relaxes tone of the prostrate smooth muscle, prostrate capsule, bladder neck, and proximal urethra. It competitively and selectively binds to the postsynaptic alpha1 -adrenergic receptors in the lower urinary tract. Alfuzosin also relaxes sympathetic nervous stilmulation, reduces resting urethral pressure and inhibits urethral hypertonia-induced sympathetic nervous stimulation.
Pharmacokinetics
Extended release alfuzosin is absorbed slowly with a mean maximum plasma concentration Cmax of 18.6mcg/lit at approx nine hours. Because the extent of absorption is decreased by 50% in fasting conditions, extended release alfusozin shoud be taken immediately after a meal.
The agents bioavailability is 49% and the mean area under the mean area-under-the plasma concentration curve over 24 hrs (AUC24) is 238mcg hour/liter.Extended release alfuzosin undergoes extensive hepatic metabolism that promptly involves cytochrome P450 isoenzyme CYP3A4
Interaction with Food:
Extended release alfusozin shoud be taken immediately after a meal.Swallow whole. Do not chew or crush
Manufacturer Details